For public health protection, informed decision-making relies on having a robust foundation of evidence concerning risks and their prevention. Application of an evidence-based framework depends on the availability of pertinent, scientifically sound data generated by well-directed and valid research endeavors. In this essay, we address the current state of research in humans and the evidential base concerning high-concentration delta-9-tetrahydrocannabinol (delta-9-THC) products, which are readily available in the United States. Furthermore, we explore the intricate challenges faced in carrying out research on these products, which reflect the full range of study design issues: measurement of exposure and outcomes, confounding, selection bias, and the generalizability of findings. We offer recommendations to guide future research toward providing more informative evidence. By following these recommendations, researchers and funders on this emerging topic could move toward generating the valid and comprehensive evidence needed to effectively inform public health initiatives and guide policy decisions regarding high-concentration delta-9-THC products and their use. The urgency of generating such evidence cannot be overstated, given the widespread legalization and increasing availability and use of these products. (Am J Public Health. 2024;114(S8):S639-S644. https://doi.org/10.2105/AJPH.2024.307724).

中文翻译：

---

加强研究高浓度 THC 产品对健康影响的方法。


对于公共卫生保护，明智的决策依赖于拥有有关风险及其预防的坚实证据基础。循证框架的应用取决于由指导良好和有效的研究工作生成的相关、科学合理的数据的可用性。在本文中，我们讨论了人类研究的现状以及有关高浓度 delta-9-四氢大麻酚 （delta-9-THC） 产品的证据基础，这些产品在美国很容易买到。此外，我们探讨了对这些产品进行研究时面临的复杂挑战，这些挑战反映了研究设计问题的全部范围：暴露和结果的测量、混杂因素、选择偏倚和研究结果的普遍性。我们提供建议，以指导未来的研究提供更多信息。通过遵循这些建议，这个新兴主题的研究人员和资助者可以朝着生成有效和全面的证据迈进，以有效地为公共卫生计划提供信息并指导有关高浓度 delta-9-THC 产品及其使用的政策决策。鉴于这些产品的广泛合法化以及越来越多的可用性和使用，生成此类证据的紧迫性怎么强调都不为过。（美国公共卫生杂志，2024 年;114（S8）：S639-S644。https://doi.org/10.2105/AJPH.2024.307724）。